NeuroMetrix, Inc. Announces Date for 2012 Full Year and Fourth Quarter Financial Results Conference Call
WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 12, 2013--
NeuroMetrix, Inc. (Nasdaq: NURO),
www.neurometrix.com,
today said it plans to issue its 2012 full year and fourth quarter
financial results before the opening of the market on
February 19, 2013.
The Company will host a conference call at
8:00 a.m., Eastern Time on
February 19, 2013 to discuss its financial results as well as business
developments affecting the Company.
The conference call may be accessed in the United States by dialing
866-825-3308 and using the confirmation code 23668017. Internationally,
the conference call may be accessed by dialing 617-213-8062 and using
the same confirmation code. The earnings press release and accompanying
condensed financial statements will be accessible from the Company's
website at www.neurometrix.com
under the "Investors" tab.
A replay of the conference call will be available starting two hours
after the call by dialing 888-286-8010, domestically and 617-801-6888,
internationally. The confirmation code to access the replay is 85981713.
The replay will be available for three months after the conference call.
About NeuroMetrix
NeuroMetrix is an innovative medical device company that develops and
markets home use and point-of-care devices for the treatment and
management of diabetic neuropathies, which affect over 50% of people
with diabetes. If left untreated, diabetic neuropathies trigger foot
ulcers that may require amputation, cause disabling chronic pain, and
increase the risk of falling in the elderly. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company’s products are used by physicians and managed care organizations
to optimize patient care and reduce healthcare costs. The company
markets the NC-stat® DPNCheck™ device, which is a rapid,
accurate, and quantitative point-of-care test for diabetic neuropathy.
This product is used to detect diabetic neuropathy at an early stage and
to guide treatment. The company also markets the SENSUS™ Pain Management
System for treating chronic pain, focusing on physicians managing
patients with painful diabetic neuropathy. The company has additional
therapeutic products in its pipeline. For more information, please visit http://www.neurometrix.com.
Source: NeuroMetrix, Inc.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
